Published by MyelinWatch:
PTD802 · PTD802 targets the GPR17 receptor and is being developed as a possible way to guide immature cells toward becoming myelin-making cells.
PTD802 targets the GPR17 receptor and is being developed as a possible way to guide immature cells toward becoming myelin-making cells.
Preparing for a first study in people
The FDA has allowed a first study to proceed; it is not listed as started.
The FDA has permitted a first-in-human study, initially in healthy volunteers. Permission is not evidence that anyone has received the drug or that it works in MS.
The study is a permitted next step, not an available treatment. No MS study or patient benefit is established.
The FDA allowed a planned first study of PTD802 to proceed. The public listing reviewed here does not show that the study has started. PTD802 is an oral drug designed to help immature cells develop into cells that make myelin.
Source: Pheno Therapeutics — official company announcement ↗
